Office: Old Road Campus Research Building (off Roosevelt Drive), Headington, Oxford, OX3 7DQ
Lab: Radiobiology Research Institute, Churchill Hospital, Headington, Oxford
Specialist Training: Cambridge University Hospitals NHS Foundation Trust, UK
Fellowship Training: Peter MacCallum Cancer Centre, Melbourne, Australia
Born in Edinburgh, but growing up and schooled in South Oxfordshire, I did initial medical training at Oxford (Corpus Christi College) and Edinburgh Universities, followed by registrar training as an ACF/ACL in Cambridge from 2007 to 2016. During this time, I did my PhD with Professor David Neal on the molecular genetics of prostate cancer at the CRUK Cambridge Institute. I undertook specialty fellowship training with Associate Professor Declan Murphy at the Peter MacCallum Cancer Centre in Melbourne, Australia from 2016 to 2017 before appointment by Professor Freddie Hamdy to an academic consultant post in Oxford in April 2017.
MA(Oxon), MBChB, PhD(Cantab), FRCS(Urol)
Cancer Research UK Clinician Scientist
- Senior Fellow in Robotic Surgery
- Honorary Consultant Urologist
Current Research Interests
My research goal is to provide a robust molecular platform for accurate decision-making in early stage prostate cancer. I have spent my scientific training investigating how individual genes or groups of genes have driven prostate cancer behaviour. My PhD thesis investigated the role of HES6 as a transcriptional driver in castrate resistant prostate cancer – we found that this single gene fundamentally changed the nature of prostate cancer cells. During this time I was funded by the Cambridge Biomedical Research Centre (NIHR) and GlaxoSmithKline, and also by a Raymond and Beverly Sackler Studentship. Subsequently, I developed an interest in integrated genomics in prostate cancer risk stratification as well as disease modelling with patient derived xenografts. In October 2018, I commenced a five-year Cancer Research UK funded Clinician Scientist Fellowship to undertake the SPACE Study, a translational research programme centred on identification the ‘lethal clone’ in high risk localised prostate cancer incorporating integrated genomics of targeted biopsies, spatial transcriptomics of whole prostates and data-driven tracking of clonal phylogenetics including in micro-metastatic disease. I also have an interest in novel molecular imaging techniques such as PSMA PET-CT and their use in disease stratification and decision-making before, during and after radical therapies. I am co-chief investigator of the TRANSLATE Trial and a local investigator for the PROMOTE, PART & FINESSE trials as well as TROMBONE which is now closed.
My clinical focus is to deliver excellent and timely prostate cancer care to men referred to our team from the Oxford regional area, focussing on state-of-the-art diagnostics with multiparametric MRI and targeted transperineal biopsies, followed by robotic-radical prostatectomy (RARP) or indeed active surveillance where appropriate. Complimentary treatment modalities such as radiation or brachytherapy are provided by other members of our dedicated prostate cancer team. I have a particular interest in developments relating to minimal access surgery (MIS) surgery and simulated training, and in investigating the role of robotic surgery in locally advanced or metastatic disease.
The Use of Digital Pathology and Artificial Intelligence in Histopathological Diagnostic Assessment of Prostate Cancer: A Survey of Prostate Cancer UK Supporters.
Rakovic K. et al, (2022), Diagnostics (Basel), 12
The provision of prostate cancer patient information leaflets on an electronic tablet: A further step to paperless health-care provision
Miah S. et al, (2022), Urology Annals, 14, 156 - 161
Genomic sequencing in oncology: Considerations for integration in routine cancer care
Rahman B. et al, (2022), European Journal of Cancer Care
Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse.
Taavitsainen S. et al, (2021), Nat Commun, 12
Tumour irradiation combined with vascular-targeted photodynamic therapy enhances antitumour effects in pre-clinical prostate cancer.
Sjoberg HT. et al, (2021), Br J Cancer, 125, 534 - 546